This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Global TB incidence saw a reduction of 8.7% while in India we were able to demonstrate a reduction of 16%, almost double the pace
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
Inducts advanced AI-Powered 24x7 remote patient monitoring system
Launch innovative vitamin sublingual sprays
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
The product has been in-licensed from Strides and will be commercialized by Amneal
Subscribe To Our Newsletter & Stay Updated
